RVTY

REVVITY, INC. (RVTY) - 10-Q Summary for Period Ended June 29, 2025

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Revvity, Inc., a leading provider of health science solutions, for the three and six months ended June 29, 2025. The company operates through two reportable segments: Life Sciences (Life Sciences Solutions and Software) and Diagnostics (Immunodiagnostics and Reproductive Health). Effective in fiscal year 2025, the company reorganized its operating model, integrating the majority of its Applied Genomics business into the Life Sciences segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 4% ($28.6 million) in Q2 2025 compared to Q2 2024, and 3% ($43.4 million) for the six-month period. Growth was driven by the Life Sciences segment (+5% in Q2, +3% YTD) and Diagnostics segment (+3% in Q2, +3% YTD).
• Segment Performance:
  • Life Sciences: Revenue growth was primarily driven by Software (+$17.1 million in Q2). Operating income decreased 2% in Q2 due to tariffs and product mix shifts.
  • Diagnostics: Revenue growth was driven by Immunodiagnostics and Reproductive Health. Operating income decreased 4% in Q2 due to tariffs and FX headwinds.
• Margins: Consolidated gross margin decreased 123 basis points in Q2 to 54.5%, primarily due to increased tariffs and product mix shifts. Operating margin increased 20 basis points to 12.6% due to sales volume leverage and productivity gains.
• Discontinued Operations: The company recorded a loss from discontinued operations of $1.3 million in Q2 2025, compared to a loss of $17.2 million in Q2 2024, related to the sale of its Applied, Food, and Enterprise Services businesses.
• Share Repurchases: The company repurchased 3.1 million shares for $293.0 million in Q2 2025 and 4.4 million shares for $443.0 million in the first six months of 2025.

Guidance, Outlook, and Risks

• Tariff Impact: Management estimates that recently enacted tariffs could increase cost of revenue by approximately $25 million for the current fiscal year, resulting in a gross margin decrease of approximately $20 million. Mitigation strategies include manufacturing optimization and selective pricing actions.
• Tax Outlook: The effective tax rate is expected to be approximately 20% for fiscal year 2025. The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, though it does not currently expect a material impact on 2025 earnings.
• Liquidity: The company maintains $1.5 billion in borrowing capacity under a new senior unsecured revolving credit facility (extended to 2030). As of June 29, 2025, $414.5 million remained available under the $1.0 billion stock repurchase program.
• Risks: Key risks include global economic conditions, government funding uncertainties for research, supply chain disruptions, foreign currency fluctuations, and potential impairment of significant intangible assets ($9.1 billion net).

Investor Verification Checklist

• Tariff Mitigation: Verify the effectiveness of pricing actions and manufacturing optimizations in offsetting the projected $20 million gross margin impact from tariffs.
• Software Growth: Confirm the sustainability of the Software business revenue growth, which was the primary driver for the Life Sciences segment.
• Intangible Assets: Review the valuation assumptions for the $9.1 billion in net intangible assets, particularly given the macroeconomic environment and potential for impairment.
• Discontinued Operations: Monitor the final settlement of the Applied, Food, and Enterprise Services divestiture, including the remaining $37.5 million Brand Fee expected in H2 2025.
• Debt Covenants: Ensure continued compliance with debt covenants, specifically the debt-to-capitalization ratio, given the company's substantial debt load of over $3.2 billion.